INTRODUCTION
Lung cancer leads to more deaths than the next 4 deadliest malignancies combined. 1 Clinical trials in cancer, including lung cancer, have traditionally identified patients based on histology and clinical characteristics, 2 factors that do not fully account for cancer's heterogeneity. 3 As various oncogenic driver mutations have been discovered and corresponding treatments targeting those mutations developed, survival outcomes for patients have improved. 4 Scientists have been encouraged by these benefits. Pharmaceutical companies have also taken notice; and, in the United States, annual spending on molecularly targeted therapies now exceeds spending on conventional chemotherapies. 5 This movement toward targeted therapies has been particularly embraced in non-small cell lung cancer (NSCLC), for which patients with metastatic epidermal growth factor receptor (EGFR)-mutant, anaplastic lymphoma kinase (ALK) generearranged cancers and patients with tumors that express programmed death-ligand 1 (PD-L1) staining 50% receive targeted therapies or immunotherapy before cytotoxic chemotherapies. 6, 7 The Lung Cancer Mutation Consortium demonstrated that the majority of adenocarcinomas of the lung-the most common NSCLC histology-harbored 1 of several driver mutations, and survival was superior when patients received treatment with an agent targeting the specific driver mutation in their tumor. 8 Clinical trials and therapies designed to treat specific subgroups promise to provide greater advances in patient outcomes in less time and using fewer resources. 2, 9 Since 2010, the majority of approval statements issued by the US Food and Drug Administration for lung cancer therapies are for subgroups of patients with specific biomarkers, including EGFR mutations, ALK gene rearrangements, and levels of PD-L1 staining. [10] [11] [12] [13] [14] [15] [16] [17] The importance of identifying biomarkers early in the development cycle is illustrated by the development of gefitinib. After receiving accelerated approval in 2003 for the treatment of all patients with advanced NSCLC after progression on platinum doublet chemotherapy and docetaxel, gefitinib had its approval withdrawn when confirmatory trials failed to demonstrate sufficient benefit in a nonbiomarker-specific group. 18, 19 Only later was it recognized that nearly all responding patients harbored EGFR exon 19 deletions or exon 21 leucine-to-arginine substitution at position 858 (L858R) mutations. 6 In 2015, gefitinib was approved again, this time for the treatment of patients who had NSCLC with these specific mutations.
The American Society of Clinical Oncology recognizes the potential of biomarker-driven research and recently emphasized that it is imperative for trial sponsors to develop a comprehensive biospecimen bank for each trial. 2 Although archival tissue may be appropriate for the evaluation of predictive biomarkers, it is often insufficient in quantity or quality. Fine-needle aspirations or bronchoscopic biopsies are often insufficient for predictive biomarker validation. [20] [21] [22] [23] Even when there is ample tissue, it may not accurately reflect the relevant biology. This can occur based on treatment-emergent changes, such as EGFR threonine-to-methionine substitution at position 790 (T790M) mutations, which occur after treatment with an EGFR inhibitor. In addition, molecules of interest may deteriorate as time passes. 24 In January 2013, our program had a tremendous increase in accrual to studies that required patients to undergo biopsies and wait for tissue to be analyzed before enrollment. Therefore, we sought to explore ways in which this design altered the clinical trial process. This included analysis of the following aspects: 1) duration of screening, 2) enrollment versus screen failure, 3) causes of screen failure, and 4) the ability of enrolled patients to yield meaningful efficacy data by undergoing the first set of protocol-required imaging. (Table 1) . Relying on patient charts, electronic health records, and billing records, we identified the date of consent and, as appropriate, the dates of biopsy, screen failure, treatment, and first radiographic assessment.
MATERIALS AND METHODS
A trial was categorized as requiring a biopsy if its inclusion and exclusion criteria called for procurement of fresh tissue and central testing with a specific result as a prerequisite to enrollment. The biopsy requirement was considered waived when there was an availability of recently procured tissue that satisfied screening requirements, which included no intervening therapy between tissue procurement and first treatment on the protocol for which the patient was screening. Because some of these trials allowed the inclusion of confirmed biomarkernegative patients in specific cohorts, patients who enrolled on biomarker-negative cohorts were considered biomarker-eligible. Trials without a biomarker requirement and those in which a biomarker requirement could be satisfied with archival tissue, even when obtained before intervening therapy, were considered to be trials that did not require a biopsy (Table 2) .
Screening duration was defined as the days from consent to either screen failure or intervention (infusion or oral ingestion of study drug). Protocols called for the first radiographic assessment to be done at different time points (range, 3-9 weeks; median, 6 weeks). To evaluate the number of enrolled patients who withdrew before the first radiographic assessment, we evaluated patients' withdrawal from study in relation to the first protocol-specific, required radiographic assessment.
If a patient consented for the same trial more than once, then the earliest date of consent and the latest date of screen failure were recorded, and the entire event was considered to be 1 screening incident. This tended to occur because of issues that emerged during screening (ie, brain metastases requiring treatment). Some protocols required these patients to be screen failed and then rescreened. If a patient signed consent and screened for more than 1 clinical trial, then each trial for which the patient screened was considered a unique screening incident.
Statistical Analysis
Clinical characteristics were compared between patients who consented to trials with biopsy requirements and those who consented to trials without biopsy requirements using the chi-square tests or Fisher's exact tests for categorical variables and t tests or Wilcoxon tests for continuous variables. Values were summarized using the (Table 2) .
We then modeled the outcome of screen fail (yes/ no) using a generalized estimating equations logistic regression model. Variables included in the model were biopsy requirement (yes/no), age, sex, and, as our clustered effect, the trial on which the patient was enrolled (to account for potentially correlated patients within each trial). From this model, odds ratios and 95% confidence intervals were extracted for each variable (Table 3) .
Finally, we performed a subgroup analysis that included only the patients who did not screen fail to establish whether patients enrolled in trials that required biopsies had shorter times to intervention by constructing Kaplan-Meier curves and formally comparing the groups using the log-rank test (Fig. 1) . All analyses were A randomized, open-label, phase 2 study evaluating LY2875358 plus erlotinib and LY2875358 monotherapy in MET diagnostic-positive patients with acquired resistance to erlotinib NCT01577745
A phase 1, multicenter, open-label, dose-escalation, and dose-expansion study evaluating the safety, tolerability, and pharmacokinetics of MEDI0639 as a single agent and in combination therapy for adult patients with advanced solid tumors, including small cell lung cancer NCT01685060
A phase 2, multicenter, single-arm study of oral LDK378 in adult patients with ALK-activated NSCLC previously treated with chemotherapy and crizotinib NCT01465802
A phase 2 study of dacomitinib in advanced NSCLC (postchemotherapy or select first-line patients) to evaluate prophylactic intervention on dermatologic and gastrointestinal adverse events and patient-reported outcomes NCT01827267 Phase 2 study of neratinib and neratinib plus temsirolimus in patients with NSCLC carrying known HER2-activating mutations NCT01871805
A phase 1/2 study of the ALK inhibitor CH5424802/RO5424802 in patients with ALK-rearranged NSCLC previously treated with crizotinib NCT00688116
A phase 1 study of the HSP90 inhibitor ganetespib administered twice weekly in patients with solid tumors NCT01348126
A randomized, phase 2b/3 study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in patients with stage IIIB or IV NSCLC NCT01798485
A randomized, phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma NCT01784640
A phase 1b dose-escalation study of pemetrexed and AUY922 in previously-treated patients with metastatic, nonsquamous NSCLC Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; HSP90, heatshock protein 90; MET, tyrosine-protein kinase Met (hepatocyte growth factor receptor); PD-L1, programmed death-ligand 1; T790M, threonine to methionine substitution at position 790 in EGFR; TKI, tyrosine kinase inhibitor. a Patients who were biomarker-negative were eligible for select study cohorts within the trials.
performed using SAS version 9.4 (SAS Institute Inc, Cary, NC). All tests were 2-sided, and P values < .05 were considered statistically significant.
RESULTS
In total, 368 screening incidents occurred on 19 trials over the 2-year period (Fig. 2) , and 285 screening incidents occurred for studies in which a biopsy was required. 
Screening Duration
The median duration of screening incidents for patients who had the biopsy requirement waived was 24 days, whereas the median duration of screening incidents for patients on trials that did not require a biopsy was 15 days (median, 24 vs 15 days; P 5 .002; Wilcoxon test). Screening duration was clearly longer for screening incidents that required a new biopsy (median, 35 days) compared either with patients who had the new biopsy requirement waived (35 vs 24 days; P 5 .001; Wilcoxon test) or with patients who did not require a new biopsy (35 vs 15 days; P < .001; Wilcoxon test). Despite increased experience with this study design over the 2-year period evaluated, screening duration did not improve over time (35.2 days in 2013 vs 35.9 days in 2014).
Causes of Screen Failure
Biomarker positivity on the parent trials ranged from 53% to 61%, with only a small percentage of biomarkernegative patients being allowed to enroll in specific cohorts. 9, 25 Screen failures on trials requiring a biopsy were most commonly because of ineligibility based on the biomarker (61 of 84 patients; 72.6%), as anticipated. However, although worsening performance status was an uncommon cause of screen failures for patients on trials that did not require a biopsy, declining performance status led to the majority of screen failures of biomarkereligible patients on trials that did require a biopsy (56.5% vs 13.6%; P 5 .005; Fisher's exact test).
Failure to Stay on Study to the First Radiographic Assessment
With the recognition that many screen failures in trials requiring biopsies were caused by worsening performance status during screening, we sought to evaluate whether enrolled patients were more likely to withdraw before the efficacy of the study agent could be adequately assessed. Patients who withdrew after enrollment but before treatment (1 patient who completed the biopsy requirement and 3 who had it waived) were excluded from this analysis. When comparing trials that did and did not require biopsies, there was no difference in the likelihood of failing to stay on the study until the first protocol-required radiographic assessment (15 of 103 enrolled patients [14. 6%] who completed biopsies, 4 of 38 (10.5%) with waived biopsies, and 4 of 60 (6.7%) on trials that did not require biopsies; P 5 .306; chi-square test). Original Article
DISCUSSION
The current analysis demonstrates that the biopsy requirement with the additional biomarker testing was associated with an increased screening duration and an increased rate of screen failures, which were driven in part by worsening performance status during screening. Trials requiring tissue as a prerequisite to enrollment are particularly labor intensive, 26 and even more so when that tissue must be from a fresh biopsy. The various divisions and departments in such a screening process include, but are not limited to, medical oncology, pathology, and radiology. 27 Although it is possible that our site is an outlier with regard to screening duration, we believe this is unlikely, and other institutions have similarly observed that a biopsy requirement was associated with increased screening times and rates of screen failure. 28 On the basis of the large numbers of patients we accrued to studies of this design, we exhaustively evaluated ways to expedite the process. We observed that, in addition to the delays related to interdepartmental communication and the time taken to evaluate specimens by the study sponsor, mundane issues, such as missing the last parcel delivery service pick-up on Thursdays, could lead to a 3-day delay.
Because nearly one-half of the patients on the parent trials were biomarker-negative, it is surprising that the disparity in the rate of screen failure was not greater. Some biomarker-negative patients were enrolled, but the great majority of patients were enrolled in cohorts that required positive biomarker status. Patients with cancer are often self-motivated to participate in clinical trials 29 ; and, although a patient who does not pursue a clinical trial typically will have received treatment within 1 or 2 weeks at our institution, patients are willing to wait to access experimental therapies. These trials were exciting to patients regardless of the additional biopsy requirements, and the rate of withdrawal of consent was quite low. The overall screen failure rate indicates that trials of this design can be conducted in a population that is not "highly selected" when the biomarker is relatively common in the screened population. However, the exclusion of a higher percentage of otherwise eligible patients who were unable to enroll based on worsening performance status demonstrates a potential bias introduced with this study design. Furthermore, 7 biomarker-eligible patients withdrew before receiving study drug. Some of these were patients who underwent a biopsy and were randomized to control arms of studies from which they then chose to withdraw, which is another issue that deserves further study.
We observed that similar percentages of patients were unable to remain on study long enough to yield optimal radiographic data. It is possible that this indicates little difference in the population of patients enrolled on trials, regardless of a biopsy requirement. However, it is also possible that worsening performance status in enrolled patients was counterbalanced by the inability of the patients with the most tenuous performance status to complete screening.
Although there is consensus regarding the value of obtaining tissue from clinical trial participants to the development of the right drugs for the right patients, investigators may wish to find ways to expedite the procurement of tissue using new biomarker-acquisition techniques (ie, blood assays for biomarker testing) and minimizing the challenges to enrollment that tissue procurement may present. Efficacies of liquid biopsies are improving, but it is unclear that they are ready to replace traditional biopsies. [30] [31] [32] Coordination between radiology, pathology, and oncology departments is key to ensuring that patients with NSCLC who are on trials that require a biopsy receive the best opportunity to benefit from clinical trial participation. Further evaluation of trials requiring a new biopsy with specific results required for enrollment and the ways in which studies of this design differ from traditional study designs are warranted.
